Traci Ryan, MD
Neurology · Tacoma, WANPI 1407847650
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.6% of the total across 16 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 11 manufacturers, the largest accounting for just 19.3% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for neurology clinicians in WA, where the typical reported total is $296.
Across 16 payments — averaging $19.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$60
- UCB, Inc.$53
- AstraZeneca$34
- Lilly USA, LLC$34
- Acorda Therapeutics, Inc$23
- Biohaven Pharmaceuticals, Inc.$22
- plus $87 from 5 others
What the payments were for
- Speaking & faculty fees$237%
- Food & beverage$28993%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 3 | $60 |
| UCB, Inc. | 2 | $53 |
| AstraZeneca(2 entities) | 2 | $34 |
| Lilly USA, LLC | 2 | $34 |
| Acorda Therapeutics, Inc | 1 | $23 |
| Biohaven Pharmaceuticals, Inc. | 1 | $22 |
| SK Life Science, Inc. | 1 | $21 |
| Jazz Pharmaceuticals Inc. | 1 | $20 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Novartis | 1 | $16 |
| Greenwich Biosciences, Inc. | 1 | $13 |
How this compares
$312 in reported general payments places this provider in the 50th percentile of 418 neurology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lacosamide | 20 | $1,912 |
| Memantine Hcl | 16 | $1,884 |
| Levetiracetam | 27 | $1,397 |
| Baclofen | 22 | $772 |
| Pregabalin | 16 | $689 |
| Lamotrigine | 22 | $581 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 14 | $485 |
| Nortriptyline Hcl | 15 | $418 |
| Risperidone | 25 | $337 |
| Sumatriptan Succinate | 20 | $262 |
| Donepezil Hcl | 12 | $174 |
| Primidone | 14 | $167 |
| Topiramate | 12 | $48 |
Paid to pharmacies, not to this prescriber.
Other neurology in Tacoma
- Stacy DonlonTacoma$613K
- Patrick HoganTacoma$116K
- Joseph DuongTacoma$7K
- Pavle RepovicSeattle$1.1M
- Jason AldredSpokane$1M
- Pinky AgarwalKirkland$795K
- Nathaniel WatsonSeattle$486K
- James BowenKirkland$379K
- Christyn EdmundsonSeattle$318K
- Jessica CraddockSpokane$266K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.